For appointments and enquiries, you are welcome to contact any of the agents we work with, for information in non-Japanese languages. Please hit the ‘English’ button below to see the contact list of all agents.
- Apr. 10, 2023
- Efficacy of Anti-HER2 Therapy with Trastuzumab Deluxecan in Uterine Carcinosarcoma Consistent with PDX-model predictions of efficacy, paving the way for the development of treatments for rare cancers.
- Apr. 3, 2023
- A clinical trial of Tazemetostat for pediatric and AYA patients with malignant tumors which have no standard treatment or which is refractory to standard treatment using Patient-Proposed Healthcare Service (NCCH2214/ TURTLE trial) to improve drug access for pediatric and AYA patients with refractory tumors.
- Feb. 20, 2023
- NCC Announces Positive Top-Line Results of Japan-led international Investigator-Initiated Registration-Directed Phase III Study Evaluating Palbociclib Plus Tamoxifen in Patients with Hormone Receptor-positive, HER2-negative Advanced or Metastatic Breast Cancer (NCCH1607/PATHWAY trial)
- Dec. 8, 2022
- Asian multicenter prospective study (CHOICE study) to elucidate the pathogenesis of cholangiocarcinoma(including FGFR2-rearranged) launched
- Nov. 2, 2022
- Yusuke Okuma has been awarded “Best of the AACR Journals”